TBX1 and neoplasm: CAFs mediate tumor progression and therapeutic resistance by inducing EMT, activating survival signaling pathways and stem-related procedures, as well as metabolic reprogramming; this highlights the possibility of explicitly eliminating the progression of some tumor subtypes by targeting CAFs with tumor-promoting effects [21].